HC Wainwright Forecasts Stronger Earnings for FocalTherics

Key Points

• HC Wainwright raised its FY2026 EPS forecast for FocalTherics to a loss of $0.71 per share from a projected loss of $0.82, and maintained a Buy rating with a $10 price target.
• FocalTherics reported a quarterly loss of $0.10 per share, better than analysts’ $0.18 loss estimate, on revenue of $9.83 million.
• Analyst views are mixed, but MarketBeat lists a Moderate Buy consensus rating and an average price target of $9.67; shares opened at $3.52 and were reported up 6%.

FocalTherics (NASDAQ:FOCL - Free Report) - Equities research analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of FocalTherics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.71) for the year, up from their prior forecast of ($0.82). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for FocalTherics' current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for FocalTherics' Q4 2026 earnings at ($0.16) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.05) EPS, FY2027 earnings at ($0.43) EPS, FY2029 earnings at $0.03 EPS and FY2030 earnings at $0.21 EPS.

FOCL has been the topic of a number of other reports. Weiss Ratings reissued a "sell (d-)" rating on shares of FocalTherics in a research report on Monday, August 17th. Mizuho initiated coverage on shares of FocalTherics in a report on Friday, July 17th. They issued an "outperform" rating and a $15.00 price objective on the stock. Piper Sandler reiterated a "neutral" rating and set a $4.00 target price on shares of FocalTherics in a research note on Friday, August 14th. Finally, Wall Street Zen raised FocalTherics from a "sell" rating to a "hold" rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $9.67.

FocalTherics Trading Up 6.0%

Shares of FocalTherics stock opened at $3.52 on Tuesday. FocalTherics has a 52-week low of $1.82 and a 52-week high of $6.40. The business has a 50 day moving average price of $4.21. The company has a quick ratio of 1.38, a current ratio of 1.60 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.08. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%. The firm had revenue of $9.83 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in FocalTherics stock. Rock Springs Capital Management LP raised its stake in FocalTherics (NASDAQ:FOCL - Free Report) by 7.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,378,000 shares of the company's stock after buying an additional 91,500 shares during the period. Rock Springs Capital Management LP owned approximately 3.68% of FocalTherics worth $5,126,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 62.74% of the company's stock.

Insider Transactions at FocalTherics

In other news, Director Joshua Levine acquired 10,000 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 45,000 shares of the company's stock, valued at $213,750. The trade was a 28.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David R. Horn acquired 10,000 shares of the stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at $47,500. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 116,000 shares of company stock valued at $551,000 over the last three months. 10.10% of the stock is owned by corporate insiders.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.